Completion↦Biobanking↦Publication↦Analytical Results
What is it? Why is it important?
The study close-out-visit marks the end of the study. The collection of Biological Material (BM) or Health-Related-Personal-Data (HrPD) is no longer possible. In order to proceed with the evaluation of the study the:
- Collected BM is analysed
- Data (e.g. HrPD) is exported imported into a statistical software package for the statistical analysis
Upon analysis (e.g. based on the study protocol) results are published in order to share findings with a broader research community (e.g. scientific journals, scientific conferences)
When publicizing research results the following aspects must be considered:
- Data protection aspects: results are summarized and not presented based on individual donor results
- Donor rights to information: information regarding personal results and study outcome
- Incidental findings: the unexpected and unintended finding beyond the aim of a study
More
Incidental findings are unexpected findings that emerge during research, but are beyond the aims of the study or research project. Incidental findings can be clinically relevant to a donor. Disclosing information about incidental findings to donors may be beneficial, but it may also be harmful, and potentially unwanted.
Donors have the right to be informed and the right to abstain from receiving information (e.g. study results, incidental findings). These rights are documented in PIS/ICF, and the SP-INV/Site-INV is required to know and respect the wishes of a donor.
In some instances and upon EC approval this right can be sidestepped. This is especially the case, when the information is deemed crucial to a donor`s current and ongoing safety and health.
What do I need to do?
In a scientific publication:
- Acknowledge the biobank from which BM was obtained and needed for the generation of research results
- Ensure results are presented in a form, that prevents the identification of individual donors
Inform donors of research results:
- As specified in the study protocol, and/or biobank regulations, and/or donor request.
- Based on:
- Study donor rights (e.g. wish to be informed, or not to be informed regarding incidental findings)
- Defined contact person (e.g. treating physician (e.g. SP-INV/Site-INV), nurse, research associate)
- Defined communication mean (e.g. by phone, email, letter, in person)
In the event a donor abstains from being informed about incidental findings, but you (e.g. SP-INV/Site-INV, researcher) deem the information to be crucial for the ongoing safety/health of the person, contact the EC to discuss grounds for sidestepping donor rights.
Where can I get help?
Your local CTU↧ can support you with experienced staff regarding this topic
Basel, Departement Klinische Forschung, CTU, dkf.unibas.ch
Lugano, Clinical Trials Unit, CTU-EOC, www.ctueoc.ch
Bern, Clinical Trials Unit, CTU, www.ctu.unibe.ch
Geneva, Clinical Research Center, CRC, crc.hug.ch
Lausanne, Clinical Research Center, CRC, www.chuv.ch
St. Gallen, Clinical Trials Unit, CTU, www.kssg.ch
Zürich, Clinical Trials Center, CTC, www.usz.ch
The Swiss Biobanking Platform (SBP) can provide you with support on this topic.
External Links
Swissethics – see in particular
- Topics/Position papers/Incidental findings
Publications PubMed
PMID: 31462969
Jui-Chu Lin et al. Managing « incidental findings » in biobank research